Routine assessment and monitoring of cognitive functions should be embedded in MS care to detect relapse-related changes and progressive decline. Identifying fluid and MRI biomarkers of cognitive dysfunction may help individuate novel targets and specific treatments.
Meo et al. (Mon,) studied this question.